Exercise as a therapeutic tool to prevent mitochondrial degeneration in nonalcoholic steatohepatitis

European Journal of Clinical Investigation

Volumn 43, Issue 11, 2013, Pages 1184-1194

  Gonçalves, Inês O ^a   Oliveira, Paulo J ^b   Ascensão, António ^a   Magalhães, José ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Mitochondrial function; Physical (in)activity; Training; Treatment

Indexed keywords

ANTILIPEMIC AGENT; ANTIOBESITY AGENT; CASPASE 3; CASPASE 7; CATALASE; CYTOCHROME C; CYTOKERATIN 18; GLUTATHIONE; INSULIN SENSITIZING AGENT; REACTIVE OXYGEN METABOLITE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; SUPEROXIDE DISMUTASE; THIOREDOXIN;

AEROBIC CAPACITY; BODY WEIGHT; CALORIC RESTRICTION; CELL DEATH; DIABETES MELLITUS; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENZYME ACTIVITY; EXERCISE; FATTY ACID OXIDATION; HISTOPATHOLOGY; HUMAN; HYPERLIPIDEMIA; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIVER CELL; LIVER INJURY; METABOLIC RATE; MITOCHONDRIAL DNA DISORDER; MITOCHONDRIAL MEMBRANE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PATHOGENESIS; PHYSICAL ACTIVITY; PHYSICAL INACTIVITY; PRIORITY JOURNAL; REVIEW; VIRUS HEPATITIS; WILSON DISEASE; COMPLICATION; KINESIOTHERAPY; LIVER MITOCHONDRION; MITOCHONDRIAL DISEASES; MITOPHAGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SEDENTARY LIFESTYLE;

EXERCISE THERAPY; HUMANS; MITOCHONDRIA, LIVER; MITOCHONDRIAL DEGRADATION; MITOCHONDRIAL DISEASES; NON-ALCOHOLIC FATTY LIVER DISEASE; SEDENTARY LIFESTYLE;

EID: 84885421216     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12146     Document Type: Review

References (114)

1. Targher G, Bertolini L, Rodella S, Lippi G, Franchini M, Zoppini G et al. NASH predicts plasma inflammatory biomarkers independently of visceral fat in men. Obesity (Silver Spring) 2008;16:1394-9.
2. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116: 1413-9.
3. Begriche K, Igoudjil A, Pessayre D, Fromenty B. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion 2006;6:1-28.
4. Pessayre D, Fromenty B. NASH: a mitochondrial disease. J Hepatol 2005;42:928-40.
5. Serviddio G, Bellanti F, Vendemiale G, Altomare E. Mitochondrial dysfunction in nonalcoholic steatohepatitis. Expert Rev Gastroenterol Hepatol 2011;5:233-44.
6. Tsochatzis EA, Papatheodoridis GV. Is there any progress in the treatment of non-alcoholic fatty liver disease? World J Gastrointest Pharmacol Ther 2011;2:1-5.
7. Ascensao A, Ferreira R, Magalhaes J. Exercise-induced cardioprotection-biochemical, morphological and functional evidence in whole tissue and isolated mitochondria. Int J Cardiol 2007;117:16-30.
8. Lumini JA, Magalhaes J, Oliveira PJ, Ascensao A. Beneficial effects of exercise on muscle mitochondrial function in diabetes mellitus. Sports Med 2008;38:735-50.
9. Ascensao A, Lumini-Oliveira J, Oliveira PJ, Magalhaes J. Mitochondria as a target for exercise-induced cardioprotection. Curr Drug Targets 2011;12:860-71.
10. Powers SK, Quindry JC, Kavazis AN. Exercise-induced cardioprotection against myocardial ischemia-reperfusion injury. Free Radic Biol Med 2008;44:193-201.
11. Zorba E, Cengiz T, Karacabey K. Exercise training improves body composition, blood lipid profile and serum insulin levels in obese children. J Sports Med Phys Fitness 2011;51:664-9.
12. Saadeh S, Younossi ZM. The spectrum of nonalcoholic fatty liver disease: from steatosis to nonalcoholic steatohepatitis. Cleve Clin J Med 2000;67:96-7, 101-4.
13. Stepanova M, Younossi ZM. Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clin Gastroenterol Hepatol 2012;10:646-50.
14. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004;40:1387-95.
15. Dassanayake AS, Kasturiratne A, Rajindrajith S, Kalubowila U, Chakrawarthi S, De Silva AP et al. Prevalence and risk factors for non-alcoholic fatty liver disease among adults in an urban Sri Lankan population. J Gastroenterol Hepatol 2009;24:1284-8.
16. Adams LA, Angulo P, Lindor KD. Nonalcoholic fatty liver disease. CMAJ 2005;172:899-905.
17. Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002;123:1705-25.
18. Strauss RS, Barlow SE, Dietz WH. Prevalence of abnormal serum aminotransferase values in overweight and obese adolescents. J Pediatr 2000;136:727-33.
19. Charlton M. Noninvasive indices of fibrosis in NAFLD: starting to think about a three-hit (at least) phenomenon. Am J Gastroenterol 2007;102:409-11.
20. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998;114:842-5.
21. Day CP. From fat to inflammation. Gastroenterology 2006;130:207-10.
22. Pan M, Cederbaum AI, Zhang YL, Ginsberg HN, Williams KJ, Fisher EA. Lipid peroxidation and oxidant stress regulate hepatic apolipoprotein B degradation and VLDL production. J Clin Invest 2004;113:1277-87.
23. Rector RS, Thyfault JP, Uptergrove GM, Morris EM, Naples SP, Borengasser SJ et al. Mitochondrial dysfunction precedes insulin resistance and hepatic steatosis and contributes to the natural history of non-alcoholic fatty liver disease in an obese rodent model. J Hepatol 2010;52:727-36.
24. Jou J, Choi SS, Diehl AM. Mechanisms of disease progression in nonalcoholic fatty liver disease. Semin Liver Dis 2008;28:370-9.
25. Wei Y, Rector RS, Thyfault JP, Ibdah JA. Nonalcoholic fatty liver disease and mitochondrial dysfunction. World J Gastroenterol 2008;14:193-9.
26. McBride HM, Neuspiel M, Wasiak S. Mitochondria: more than just a powerhouse. Curr Biol 2006;16:R551-60.
27. Mitchell P. Coupling of phosphorylation to electron and hydrogen transfer by a chemi-osmotic type of mechanism. Nature 1961;191:144-8.
28. Skarka L, Ostadal B. Mitochondrial membrane potential in cardiac myocytes. Physiol Res 2002;51:425-34.
29. Hedskog L, Zhang S, Ankarcrona M. Strategic role for mitochondria in Alzheimer's disease and cancer. Antioxid Redox Signal 2012;16:1476-91.
30. Rajender S, Rahul P, Mahdi AA. Mitochondria, spermatogenesis and male infertility. Mitochondrion 2010;10:419-28.
31. Bournat JC, Brown CW. Mitochondrial dysfunction in obesity. Curr Opin Endocrinol Diabetes Obes 2010;17:446-52.
32. Szendroedi J, Phielix E, Roden M. The role of mitochondria in insulin resistance and type 2 diabetes mellitus. Nat Rev Endocrinol 2012;8:92-103.
33. Grattagliano I, Russmann S, Diogo C, Bonfrate L, Oliveira PJ, Wang DQ et al. Mitochondria in chronic liver disease. Curr Drug Targets 2011;12:879-93.
34. Hruszkewycz AM. Evidence for mitochondrial DNA damage by lipid peroxidation. Biochem Biophys Res Commun 1988;153:191-7.
35. Nomoto K, Tsuneyama K, Takahashi H, Murai Y, Takano Y. Cytoplasmic fine granular expression of 8-hydroxydeoxyguanosine reflects early mitochondrial oxidative DNA damage in nonalcoholic fatty liver disease. Appl Immunohistochem Mol Morphol 2008;16:71-5.
36. Ma X, Li Z. Pathogenesis of nonalcoholic steatohepatitis (NASH). Chin J Dig Dis 2006;7:7-11.
37. Dianzani MU. Uncoupling of oxidative phosphorylation in mitochondria from fatty livers. Biochim Biophys Acta 1954;14:514-32.
38. Ahishali E, Demir K, Ahishali B, Akyuz F, Pinarbasi B, Poturoglu S et al. Electron microscopic findings in non-alcoholic fatty liver disease: is there a difference between hepatosteatosis and steatohepatitis? J Gastroenterol Hepatol 2010;25:619-26.
39. Droge W. Free radicals in the physiological control of cell function. Physiol Rev 2002;82:47-95.
40. Grattagliano I, Palmieri VO, Portincasa P, Moschetta A, Palasciano G. Oxidative stress-induced risk factors associated with the metabolic syndrome: a unifying hypothesis. J Nutr Biochem 2008;19:491-504.
41. Rolo AP, Teodoro JS, Palmeira CM. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic Biol Med 2012;52:59-69.
42. Koek GH, Liedorp PR, Bast A. The role of oxidative stress in non-alcoholic steatohepatitis. Clin Chim Acta 2011;412:1297-305.
43. Loguercio C, De Girolamo V, de Sio I, Tuccillo C, Ascione A, Baldi F et al. Non-alcoholic fatty liver disease in an area of southern Italy: main clinical, histological, and pathophysiological aspects. J Hepatol 2001;35:568-74.
44. Cortez-Pinto H, Chatham J, Chacko VP, Arnold C, Rashid A, Diehl AM. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. JAMA 1999;282:1659-64.
45. Perez-Carreras M, Del Hoyo P, Martin MA, Rubio JC, Martin A, Castellano G et al. Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology 2003;38:999-1007.
46. Santamaria E, Avila MA, Latasa MU, Rubio A, Martin-Duce A, Lu SC et al. Functional proteomics of nonalcoholic steatohepatitis: mitochondrial proteins as targets of S-adenosylmethionine. Proc Natl Acad Sci USA 2003;100:3065-70.
47. Trachootham D, Lu W, Ogasawara MA, Nilsa RD, Huang P. Redox regulation of cell survival. Antioxid Redox Signal 2008;10:1343-74.
48. Baskol G, Baskol M, Kocer D. Oxidative stress and antioxidant defenses in serum of patients with non-alcoholic steatohepatitis. Clin Biochem 2007;40:776-80.
49. Leclercq IA. Antioxidant defence mechanisms: new players in the pathogenesis of non-alcoholic steatohepatitis? Clin Sci (Lond) 2004;106:235-7.
50. Machado MV, Ravasco P, Jesus L, Marques-Vidal P, Oliveira CR, Proenca T et al. Blood oxidative stress markers in non-alcoholic steatohepatitis and how it correlates with diet. Scand J Gastroenterol 2008;43:95-102.
51. Nobili V, Pastore A, Gaeta LM, Tozzi G, Comparcola D, Sartorelli MR et al. Glutathione metabolism and antioxidant enzymes in patients affected by nonalcoholic steatohepatitis. Clin Chim Acta 2005;355:105-11.
52. Perlemuter G, Davit-Spraul A, Cosson C, Conti M, Bigorgne A, Paradis V et al. Increase in liver antioxidant enzyme activities in non-alcoholic fatty liver disease. Liver Int 2005;25:946-53.
53. Takami Y, Uto H, Tamai T, Sato Y, Ishida Y, Morinaga H et al. Identification of a novel biomarker for oxidative stress induced by hydrogen peroxide in primary human hepatocytes using the 2-nitrobenzenesulfenyl chloride isotope labeling method. Hepatol Res 2010;40:438-45.
54. Videla LA, Rodrigo R, Orellana M, Fernandez V, Tapia G, Quinones L et al. Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients. Clin Sci (Lond) 2004;106:261-8.
55. Bragoszewski P, Habior A, Walewska-Zielecka B, Ostrowski J. Expression of genes encoding mitochondrial proteins can distinguish nonalcoholic steatosis from steatohepatitis. Acta Biochim Pol 2007;54:341-8.
56. Serviddio G, Bellanti F, Tamborra R, Rollo T, Capitanio N, Romano AD et al. Uncoupling protein-2 (UCP2) induces mitochondrial proton leak and increases susceptibility of non-alcoholic steatohepatitis (NASH) liver to ischaemia-reperfusion injury. Gut 2008;57:957-65.
57. Jezek P. Possible physiological roles of mitochondrial uncoupling proteins-UCPn. Int J Biochem Cell Biol 2002;34:1190-206.
58. Feldstein AE, Gores GJ. Apoptosis in alcoholic and nonalcoholic steatohepatitis. Front Biosci 2005;10:3093-9.
59. Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J 1998;17:1675-87.
60. Feldstein AE, Canbay A, Angulo P, Taniai M, Burgart LJ, Lindor KD et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003;125:437-43.
61. Ribeiro PS, Cortez-Pinto H, Sola S, Castro RE, Ramalho RM, Baptista A et al. Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am J Gastroenterol 2004;99:1708-17.
62. Ramalho RM, Cortez-Pinto H, Castro RE, Sola S, Costa A, Moura MC et al. Apoptosis and Bcl-2 expression in the livers of patients with steatohepatitis. Eur J Gastroenterol Hepatol 2006;18:21-9.
63. Marra F, Gastaldelli A, Svegliati Baroni G, Tell G, Tiribelli C. Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol Med 2008;14:72-81.
64. Hengartner MO. Apoptosis: corralling the corpses. Cell 2001;104:325-8.
65. Takehara T, Tatsumi T, Suzuki T, Rucker EB 3rd, Hennighausen L, Jinushi M et al. Hepatocyte-specific disruption of Bcl-xL leads to continuous hepatocyte apoptosis and liver fibrotic responses. Gastroenterology 2004;127:1189-97.
66. Canbay A, Feldstein AE, Higuchi H, Werneburg N, Grambihler A, Bronk SF et al. Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. Hepatology 2003;38:1188-98.
67. Canbay A, Taimr P, Torok N, Higuchi H, Friedman S, Gores GJ. Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab Invest 2003;83:655-63.
68. Guicciardi ME, Gores GJ. Apoptosis: a mechanism of acute and chronic liver injury. Gut 2005;54:1024-33.
69. Canbay A, Friedman S, Gores GJ. Apoptosis: the nexus of liver injury and fibrosis. Hepatology 2004;39:273-8.
70. Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 2009;50:1072-8.
71. Sanyal AJ. NASH: a global health problem. Hepatol Res 2011;41:670-4.
72. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
73. Kaser S, Ebenbichler CF, Tilg H. Pharmacological and non-pharmacological treatment of non-alcoholic fatty liver disease. Int J Clin Pract 2010;64:968-83.
74. Rector RS, Uptergrove GM, Morris EM, Borengasser SJ, Laughlin MH, Booth FW et al. Daily exercise vs. caloric restriction for prevention of nonalcoholic fatty liver disease in the OLETF rat model. Am J Physiol Gastrointest Liver Physiol 2011;300:G874-83.
75. Rector RS, Thyfault JP. Does physical inactivity cause nonalcoholic fatty liver disease? J Appl Physiol 2011;111:1828-35.
76. Schultz A, Mendonca LS, Aguila MB, Mandarim-de-Lacerda CA. Swimming training beneficial effects in a mice model of nonalcoholic fatty liver disease. Exp Toxicol Pathol 2012;64:273-82.
77. Rector RS, Thyfault JP, Morris RT, Laye MJ, Borengasser SJ, Booth FW et al. Daily exercise increases hepatic fatty acid oxidation and prevents steatosis in Otsuka Long-Evans Tokushima Fatty rats. Am J Physiol Gastrointest Liver Physiol 2008;294:G619-26.
78. Thyfault JP, Rector RS, Uptergrove GM, Borengasser SJ, Morris EM, Wei Y et al. Rats selectively bred for low aerobic capacity have reduced hepatic mitochondrial oxidative capacity and susceptibility to hepatic steatosis and injury. J Physiol 2009;587:1805-16.
79. Thoma C, Day CP, Trenell MI. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. J Hepatol 2012;56:255-66.
80. Huang MA, Greenson JK, Chao C, Anderson L, Peterman D, Jacobson J et al. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol 2005;100:1072-81.
81. Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010;51:121-9.
82. Vilar Gomez E, Rodriguez De Miranda A, Gra Oramas B, Arus Soler E, Llanio Navarro R, Calzadilla Bertot L et al. Clinical trial: a nutritional supplement Viusid, in combination with diet and exercise, in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2009;30:999-1009.
83. Bhat G, Baba CS, Pandey A, Kumari N, Choudhuri G. Life style modification improves insulin resistance and liver histology in patients with non-alcoholic fatty liver disease. World J Hepatol 2012;4:209-17.
84. Sreenivasa Baba C, Alexander G, Kalyani B, Pandey R, Rastogi S, Pandey A et al. Effect of exercise and dietary modification on serum aminotransferase levels in patients with nonalcoholic steatohepatitis. J Gastroenterol Hepatol 2006;21:191-8.
85. Magkos F. Putative factors that may modulate the effect of exercise on liver fat: insights from animal studies. J Nutr Metab 2012;2012:827417.
86. Johnson NA, George J. Fitness versus fatness: moving beyond weight loss in nonalcoholic fatty liver disease. Hepatology 2010;52:370-81.
87. He Y, Zhang H, Fu F. The effects of swimming exercise on high-fat-diet-induced steatohepatitis. J Sports Med Phys Fitness 2008;48:259-65.
88. Marques CM, Motta VF, Torres TS, Aguila MB, Mandarim-de-Lacerda CA. Beneficial effects of exercise training (treadmill) on insulin resistance and nonalcoholic fatty liver disease in high-fat fed C57BL/6 mice. Braz J Med Biol Res 2010;43:467-75.
89. Portincasa P, Grattagliano I, Lauterburg BH, Palmieri VO, Palasciano G, Stellaard F. Liver breath tests non-invasively predict higher stages of non-alcoholic steatohepatitis. Clin Sci (Lond) 2006;111:135-43.
90. Mantena SK, Vaughn DP, Andringa KK, Eccleston HB, King AL, Abrams GA et al. High fat diet induces dysregulation of hepatic oxygen gradients and mitochondrial function in vivo. Biochem J 2009;417:183-93.
91. Raffaella C, Francesca B, Italia F, Marina P, Giovanna L, Susanna I. Alterations in hepatic mitochondrial compartment in a model of obesity and insulin resistance. Obesity (Silver Spring) 2008;16:958-64.
92. Vial G, Dubouchaud H, Couturier K, Cottet-Rousselle C, Taleux N, Athias A et al. Effects of a high-fat diet on energy metabolism and ROS production in rat liver. J Hepatol 2011;54:348-56.
93. Ciapaite J, van den Broek NM, Te Brinke H, Nicolay K, Jeneson JA, Houten SM et al. Differential effects of short- and long-term high-fat diet feeding on hepatic fatty acid metabolism in rats. Biochim Biophys Acta 2011;1811:441-51.
94. Boveris A, Navarro A. Systemic and mitochondrial adaptive responses to moderate exercise in rodents. Free Radical Biol Med 2008;44:224-9.
95. Ascensao A, Lumini-Oliveira J, Machado NG, Ferreira RM, Goncalves IO, Moreira AC et al. Acute exercise protects against calcium-induced cardiac mitochondrial permeability transition pore opening in doxorubicin-treated rats. Clin Sci (Lond) 2011;120:37-49.
96. Ascensao A, Goncalves IO, Lumini-Oliveira J, Marques-Aleixo I, Dos Passos E, Rocha-Rodrigues S et al. Endurance training and chronic intermittent hypoxia modulate in vitro salicylate-induced hepatic mitochondrial dysfunction. Mitochondrion 2012;12:607-16.
97. Serviddio G, Bellanti F, Sastre J, Vendemiale G, Altomare E. Targeting mitochondria: a new promising approach for the treatment of liver diseases. Curr Med Chem 2010;17:2325-37.
98. He C, Sumpter R Jr, Levine B. Exercise induces autophagy in peripheral tissues and in the brain. Autophagy 2012;8:1548-51.
99. Barakat HA, Kasperek GJ, Dohm GL, Tapscott EB, Snider RD. Fatty acid oxidation by liver and muscle preparations of exhaustively exercised rats. Biochem J 1982;208:419-24.
100. Bielecki JW, Pawlicka E, Gorski J. Effect of exhaustive exercise on liver mitochondrial function in the rat. Acta Physiol Pol 1988;39:421-6.
101. Radeva-Domustchieva D, Russanov E. Effect of exhaustive swimming on the oxidative phosphorylation and the activity of some enzymes in rat liver mitochondria. Acta Physiol Pharmacol Bulg 1976;2:72-7.
102. Venditti P, Masullo P, Meo SD. Effect of exercise duration on characteristics of mitochondrial population from rat liver. Arch Biochem Biophys 1999;368:112-20.
103. Tate CA, Wolkowicz PE, McMillin-Wood J. Exercise-induced alterations of hepatic mitochondrial function. Biochem J 1982;208:695-701.
104. Sun L, Shen W, Liu Z, Guan S, Liu J, Ding S. Endurance exercise causes mitochondrial and oxidative stress in rat liver: effects of a combination of mitochondrial targeting nutrients. Life Sci 2010;86:39-44.
105. Venditti P, Di Meo S. Antioxidants, tissue damage, and endurance in trained and untrained young male rats. Arch Biochem Biophys 1996;331:63-8.
106. Liu J, Yeo HC, Overvik-Douki E, Hagen T, Doniger SJ, Chyu DW et al. Chronically and acutely exercised rats: biomarkers of oxidative stress and endogenous antioxidants. J Appl Physiol 2000;89:21-8.
107. Laye MJ, Rector RS, Borengasser SJ, Naples SP, Uptergrove GM, Ibdah JA et al. Cessation of daily wheel running differentially alters fat oxidation capacity in liver, muscle, and adipose tissue. J Appl Physiol 2009;106:161-8.
108. Rector RS, Thyfault JP, Laye MJ, Morris RT, Borengasser SJ, Uptergrove GM et al. Cessation of daily exercise dramatically alters precursors of hepatic steatosis in Otsuka Long-Evans Tokushima Fatty (OLETF) rats. J Physiol 2008;586:4241-9.
109. Gonçalves IO, Portincasa P, Grattagliano I, Pizarro AN, Ascensão A, Magalhães J. Habitual physical activity and liver mitochondrial function in patients with non-alcoholic fatty liver disease (NAFLD). A pilot study. Eur J Clin Invest 2012;42:80.
110. Romijn JA, Pijl H. The muscle-liver axis: does aerobic fitness induce intrahepatic protection against non-alcoholic fatty liver disease? J Physiol 2009;587:1637.
111. Krasnoff JB, Painter PL, Wallace JP, Bass NM, Merriman RB. Health-related fitness and physical activity in patients with nonalcoholic fatty liver disease. Hepatology 2008;47:1158-66.
112. Kistler KD, Brunt EM, Clark JM, Diehl AM, Sallis JF, Schwimmer JB. Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease. Am J Gastroenterol 2011;106:460-8; quiz 9.
113. King DW, Gollnick PD. Ultrastructure of rat heart and liver after exhaustive exercise. Am J Physiol 1970;218:1150-5.
114. Terblanche SE, Gohil K, Packer L, Henderson S, Brooks GA. The effects of endurance training and exhaustive exercise on mitochondrial enzymes in tissues of the rat (Rattus norvegicus). Comp Biochem Physiol A Mol Integr Physiol 2001;128:889-96.